Combination comprising paclitaxel for treating ovarian cancer

Abstract

The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.

1 . A product containing the compound of formula (I) below 
       
         
           
           
               
               
           
         
       
       in free or a pharmaceutically acceptable salt form, in combination with paclitaxel, in free or a pharmaceutically acceptable salt form. 
     
     
         2 . A method for the treatment of ovarian cancer, comprising administering, simultaneously, separately or over a period of time, to a patient in need thereof, a compound of formula (I): 
       
         
           
           
               
               
           
         
         in free or a pharmaceutically acceptable salt form, in combination with paclitaxel, in free or a pharmaceutically acceptable salt form. 
       
     
     
         3 . The method according to  claim 2 , wherein the compound of formula (I) in free or a pharmaceutically acceptable salt form is administered by intravenous or intraperitoneal route. 
     
     
         4 . The method according to  claim 2 , wherein the compound of formula (I) in free or a pharmaceutically acceptable salt form is administered by oral route. 
     
     
         5 . The method according to  claim 2 , wherein paclitaxel in free or a pharmaceutically acceptable salt form is administered by intravenous or intraperitoneal route. 
     
     
         6 . A pharmaceutical composition containing, as active principle, the product of  claim 1 , as well as at least one non-toxic excipient. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , which is in a liquid form suitable for intravenous or intraperitoneal administration. 
     
     
         8 . The pharmaceutical composition according to  claim 7 , which contains the compound of formula (I), in free or a pharmaceutically acceptable salt form, and paclitaxel, in free or a pharmaceutically acceptable salt form, in solution in a mixture of polyoxyethylated castor oil and ethanol. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , wherein the mixture of polyoxyethylated castor oil and ethanol is such that it contains from 40 to 60% in volume of polyoxyethylated castor oil in ethanol.